Eur Heart J: The effect of dapagliflozin on ventricular arrhythmia, cardiac arrest or sudden death

Recently, the heart blood vessels magazine field authority Eur Heart published a research article on J, the study was designed to evaluate the dapagliflozin reduced ejection fraction in heart failure patients with ventricular (HFrEF) arrhythmia and sudden death affect the incidence
.

The study was a post-mortem analysis of the DAPA-HF trial.
The researchers evaluated incident reports related to serious adverse reactions and ventricular arrhythmia or cardiac arrest, as well as the judged sudden death
.

Among the 4744 patients in the DAPA-HF trial, 115 (2.
4%) patients reported severe ventricular arrhythmia (15 patients had ventricular fibrillation, 86 patients had ventricular tachycardia, and 12 patients had “other” "Ventricular arrhythmia/tachycardia, 2 patients developed torsade de pointes tachycardia)
.

Among the participants assigned to dapagliflozin, 140/2373 (5.
9%) patients had a composite outcome, compared with 175/2371 (7.
4%) patients in the placebo group [hazard ratio of 0.
79 (95% confidence) The interval is 0.
63-0.
99), P=0.
037], and the effect is consistent in each component of the composite outcome
.

It can be seen that adding dapagliflozin to the conventional treatment of HFrEF patients can reduce the risk of any severe ventricular arrhythmia, cardiac arrest or sudden death
.

Original source:

James P Curtain.